To the Editor,
Anesthesia and surgery induce a number of metabolic derangements particularly in those with type-2 diabetes (T2D). [1] [2] [3] Hyperglycemia (blood glucose [ 11 mmol/L) is associated with risks including increased surgical site infection, thromboembolism, and myocardial infarction. 1, 2 Lowering glucose by even 1 mmolÁL -1 is reported to reduce surgical site infections. 4 Canadian population trends suggest we are increasingly likely to care for hyperglycemic patients perioperatively; accordingly, best management practices should be investigated and developed.
Following institutional ethical approval, we surveyed 2,415 practicing members of the Canadian Anesthesiologists Society with a six-question survey designed to assess practice patterns regarding perioperative diabetes management (eTable, full survey available as Electronic Supplementary Material). The survey was initially emailed on 22 June 2018, with two reminders sent to non-responders, and the survey closed six weeks later. Overall, we received 223 (9.2%) responses.
Our survey revealed that half (112; 50.2%) of respondents work in a department with a formal policy regarding the perioperative management of diabetes medications. Interestingly, 221 (97%) respondents hold all oral glucose-lowering medications on the day of surgery (Table) . 1 This survey raises several important issues regarding current perioperative management of patients with T2D. Discrepancies between current evidence, guidelines, and actual practice suggests implementing any new interventions into routine practice might remain an important barrier. Additionally, advice on perioperative medication use is often managed using medical directives executed by preadmission nurses, and simply holding all medications makes it easier to maintain consistency, which can avoid unnecessary cancellations. Indeed, certain medications should be withheld, such as insulin secretagogues to avoid inducing hypoglycemia, and sodium glucose-cotransporter 2 (SGLT-2) inhibitors to avoid normoglycemic diabetic ketoacidosis (Table) . 1, 2, 5 Several other glucose-lowering medications (i.e., thiazolidinediones, dipeptidyl peptidase-4 [DPP-4] inhibitors, glucagon-like peptide-1 analogues, and metformin) appear safe to continue perioperatively and may even help to manage glucose following surgery. 1, 2 Although this strategy has garnered support by some anesthesia societies, 1 correlate with a two-fold increase in all-cause, and a four-fold increase in cardiovascular-related mortality and thus may represent a reasonable target. 1, 3 This questions whether reducing blood glucose to\12 mmolÁL -1 actually offers any benefit, and how best to accomplish this. Although insulin can be used, variable degrees of insulin resistance that occur following surgery make dosing challenging, and risks the development of profound hypoglycemia. 2, 4 Notably, patients with T2D treated with glucose-lowering medications prior to surgery appear to have improved outcomes relative to those who remain untreated, and their perioperative continuation may offer some benefit to maintain more physiologic regulation. 3 Perhaps some universal guidelines may help facilitate the optimization and management of hyperglycemic surgical patients.
As the incidence of T2D continues to increase, anesthesiologists will have to remain dynamic and regularly re-evaluate the management of hyperglycemic patients in an attempt to continuously improve care within resources that are at times limited. 
